AZN vs. INCY: AstraZeneca vs. Incyte Stock Comparison
How do AstraZeneca (AZN) and Incyte (INCY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
AstraZeneca (AZN) and Incyte (INCY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but AZN is classified in Pharmaceuticals while INCY is classified in Biotechnology.
Incyte (INCY) trades as ordinary local shares, while AstraZeneca (AZN) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | AZN | INCY |
|---|---|---|
| Name | AstraZeneca PLC American Depositary Shares | Incyte Corp. |
| Country/Region | United Kingdom | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals | Biotechnology |
| GICS Sub-Industry | Pharmaceuticals | Biotechnology |
| Market Capitalization | 289.14 billion USD | 24.39 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | May 12, 1993 | November 4, 1993 |
| Security Type | ADR | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | AZN | INCY |
|---|---|---|
| Total Return (1Y) | 12.64% | 14.06% |
| Total Return (3Y, Annualized) | 15.75% | 32.03% |
| Total Return (5Y, Annualized) | 10.63% | 12.69% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | AZN | INCY |
|---|---|---|
| Volatility (1Y, Annualized) | 28.21% | 33.19% |
| Beta (5Y) | 0.22 | 0.78 |
| Max Drawdown (5Y) | -27.87% | -40.50% |
| Avg. Volume (3M) | 3.14M | 1.58M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | AZN | INCY |
|---|---|---|
| Sharpe Ratio (1Y) | 0.30 | 0.29 |
| Sortino Ratio (1Y) | 0.44 | 0.46 |
Profitability
ROE (TTM)
Both AstraZeneca (AZN) at 22.57% and Incyte (INCY) at 7.84% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.57%
- Max
- 109.18%
- AZN
- 22.57%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.84%
- Max
- 109.18%
- INCY
- 7.84%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
For every dollar of sales, both AstraZeneca (AZN) at 17.68% and Incyte (INCY) at 6.71% retain more as net profit than most peers, landing in the top net margin quartile of their industries.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
17.68%
- Max
- 18.05%
- AZN
- 17.68%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.71%
- Max
- 18.05%
- INCY
- 6.71%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both AstraZeneca (AZN) at 29.57% and Incyte (INCY) at 33.72% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
29.57%
- Max
- 83.12%
- AZN
- 29.57%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
33.72%
- Max
- 83.12%
- INCY
- 33.72%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | AZN | INCY |
|---|---|---|
| ROE (TTM) | 22.57% | 7.84% |
| ROA (TTM) | 8.59% | 17.78% |
| Net Margin (TTM) | 17.68% | 6.71% |
| Operating Margin (TTM) | 29.57% | 33.72% |
| Gross Margin (TTM) | 81.78% | 56.02% |
Growth
Revenue Growth
Both AstraZeneca (AZN) at 8.63% and Incyte (INCY) at 21.22% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Incyte (INCY) at 4,173.33% clears its industry range for EPS growth, a much stronger earnings trajectory than AstraZeneca (AZN) at 45.33%, which is closer to a typical peer reading.
Growth Metrics
| Metric | AZN | INCY |
|---|---|---|
| Revenue Growth (YoY) | 8.63% | 21.22% |
| Revenue Growth (3Y CAGR) | 9.82% | 14.84% |
| EPS Growth (YoY) | 45.33% | 4,173.33% |
| EPS Growth (3Y CAGR) | 45.80% | 61.56% |
Financial Strength
Current Ratio (MRQ)
Incyte (INCY) at 3.84 keeps current ratio within its industry’s typical mid-range, while AstraZeneca (AZN) at 1.01 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for AZN.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.01
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- AZN
- 1.01
- Min
- 0.10
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.84
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- INCY
- 3.84
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Incyte (INCY) at 0.01 keeps leverage in the lower quartile, while AstraZeneca (AZN) at 0.66 sits in the higher-leverage quartile.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.66
- Max
- 1.42
- AZN
- 0.66
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.01
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- INCY
- 0.01
- Min
- 0.00
Financial Strength Metrics
| Metric | AZN | INCY |
|---|---|---|
| Current Ratio (MRQ) | 1.01 | 3.84 |
| Debt / Equity (MRQ) | 0.66 | 0.01 |
| Net Debt / EBITDA | 1.23 | -1.88 |
Dividends
Dividend Yield (TTM)
Incyte (INCY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AstraZeneca (AZN) reports a yield of 1.73%, ranking against industry peers normally.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.73%
- AZN
- 1.73%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INCY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Incyte (INCY) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AstraZeneca (AZN) reports a payout of 45.38%, ranking against industry peers normally.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
45.38%
- AZN
- 45.38%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INCY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | AZN | INCY |
|---|---|---|
| Dividend Yield (TTM) | 1.73% | 0.00% |
| Dividend Payout Ratio (TTM) | 45.38% | 0.00% |
Valuation
P/E Ratio (TTM)
AstraZeneca (AZN) at 26.37 is near its industry’s usual P/E ratio, while Incyte (INCY) at 61.05 sits in the richer quartile — INCY needs stronger growth or earnings quality to justify the premium.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.37
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- AZN
- 26.37
- Q1
- 13.30
- Min
- 0.07
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
61.05
- Max
- 85.34
- INCY
- 61.05
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both AstraZeneca (AZN) at 4.63 and Incyte (INCY) at 4.06 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.63
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- AZN
- 4.63
- Q1
- 3.01
- Min
- 0.01
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.06
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- INCY
- 4.06
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both AstraZeneca (AZN) at 5.59 and Incyte (INCY) at 4.33 are valued close to their industries’ norm against book — neither stands out from peers.
AZN
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.59
- Max
- 13.53
- Q3
- 6.54
- AZN
- 5.59
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.33
- Max
- 13.53
- Q3
- 6.54
- INCY
- 4.33
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | AZN | INCY |
|---|---|---|
| P/E Ratio (TTM) | 26.37 | 61.05 |
| P/S Ratio (TTM) | 4.63 | 4.06 |
| P/B Ratio (MRQ) | 5.59 | 4.33 |
| Free Cash Flow Yield (TTM) | 1.95% | 5.28% |